Search Results
Your search for all items matches 49 pages
Showing 1 - 49
Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy
Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on tinengotinib, a next-generation FGFR inhibitor that seems to overcome acquired resistance and shows efficacy in patients with cholangiocarcinoma with other FGFR alterations who are not eligible...
Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab
Riccardo Lencioni, MD, of the University of Pisa School of Medicine, discusses phase III results from the EMERALD-1 study of durvalumab plus bevacizumab plus TACE (transarterial chemoembolization) in patients with embolization-eligible unresectable hepatocellular carcinoma. Compared with TACE...
R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin
R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall...
Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance
Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ...
Laura A. Dawson, MD, on Hepatocellular Carcinoma: Phase III Data on Sorafenib vs Stereotactic Body Radiation Therapy
Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings from the NRG/RTOG1112 study, which showed that stereotactic body radiation therapy (SBRT) administered prior to sorafenib vs sorafenib alone, improved outcomes in patients with advanced hepatocellular...
Laura A. Dawson, MD, on Hepatocellular Carcinoma and Liver Metastases: Recent Treatment Data on Palliative Radiotherapy
Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that compared with best supportive care alone, single-fraction whole-liver radiation therapy appears to improve hepatic pain in the majority of patients with treatment-refractory or -ineligible...
Richard S. Finn, MD, on HCC: Tislelizumab vs Sorafenib, and Their Impact on Quality of Life
Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses findings from the RATIONALE-301 study, which showed that patients with unresectable hepatocellular carcinoma (HCC) treated with first-line tislelizumab had better health-related...
Rachna T. Shroff, MD, on Biliary Tract Cancers: Recent Findings on Use of Gemcitabine, Cisplatin, and Nab-paclitaxel
Rachna T. Shroff, MD, of the University of Arizona Cancer Center, discusses phase III results from the SWOG 1815 study, which compared gemcitabine, cisplatin, and nab-paclitaxel vs gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancers. Although adding...
Treatment of AJCC Stage IV Intrahepatic Cholangiocarcinoma
This is Part 4 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss the treatment of AJCC stage IV intrahepatic cholangiocarcinoma. The...
Adjuvant Therapy in Biliary Tract Cancer
This is Part 3 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss the role of adjuvant therapy in biliary tract cancer. The patient is a ...
Second-Line Therapy and Beyond in Hepatocellular Carcinoma
This is Part 2 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss second-line therapy and beyond in hepatocellular carcinoma. The...
Front-Line Therapy in Metastatic Hepatocellular Carcinoma
This is Part 1 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss front-line therapy in metastatic hepatocellular carcinoma. The patient ...
Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab
Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor, vs lenvatinib...
Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki
Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).
Anthony B. El-Khoueiry, MD, on Hepatocellular Carcinoma: Expert Perspective on Novel Additive Strategies
Anthony B. El-Khoueiry, MD, of the University of Southern California, Norris Comprehensive Cancer Center, discusses two key phase III studies of first-line treatment in hepatocellular carcinoma: the LAUNCH trial, which explored lenvatinib combined with transarterial chemoembolization for advanced...
Ghassan K. Abou-Alfa, MD, MBA, on Hepatocellular Carcinoma: Open-Label Trial of Tremelimumab and Durvalumab
Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, discusses phase III results of the HIMALAYA trial, which showed the combination of a single priming dose of tremelimumab added to durvalumab is superior to sorafenib for...
Nilofer Saba Azad, MD, on Novel Treatment Combinations Under Study in Biliary Tract Cancers
Nilofer Saba Azad, MD, of Johns Hopkins Sidney Kimmel Cancer Center, assesses the findings from the phase III TOPAZ-1 trial, a study of durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Dr. Azad explains why the study sets a potential new...
Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib
Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements...
Richard S. Finn, MD, on Treating Hepatocellular Carcinoma With Atezolizumab, Bevacizumab, and Sorafenib
Richard S. Finn, MD, of UCLA Medical Center, discusses updated efficacy and safety data from the IMbrave150 trial of patients receiving atezolizumab plus bevacizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma (Abstract CT009).
Andrew X. Zhu, MD, PhD, on IDH1-Mutant Cholangiocarcinoma: Ivosidenib vs Placebo
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses final results from the phase III ClarIDHy study, which showed that ivosidenib may improve overall and progression-free survival compared with placebo in patients with previously treated cholangiocarcinoma and an isocitrate...
Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib
Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a front-line phase III study in advanced hepatocellular carcinoma, confirming this combination as the...
Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib
Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results showing that the novel tyrosine kinase inhibitor infigratinib may prove to be effective in treating patients with advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement...
Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resistance to the combination treatment of atezolizumab and bevacizumab in patients with advanced...
Thomas Yau, MBBS, on Advanced Hepatocellular Carcinoma: CheckMate 040 Trial of Nivolumab, Ipilimumab, and Cabozantinib
Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advanced liver cancer, but with more severe adverse events and more treatment discontinuations (Abstract 478).
Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes
Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus bevacizumab vs sorafenib is well tolerated and may represent a new standard of care in the first-line setting for...
Ghassan K. Abou-Alfa, MD, MBA, on Cholangiocarcinoma: ClarIDHy Trial of Ivosidenib vs Placebo
Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings showing improvement in progression-free survival among patients with an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib compared with a similar group that received placebo ...
Tim Meyer, PhD, and Lorenza Rimassa, MD, on Advanced Hepatocellular Carcinoma: CELESTIAL Trial of Cabozantinib
Tim Meyer, PhD, of the University College London, and Lorenza Rimassa, MD, of Humanitas Research Hospital, Milan, discuss their phase III findings on prognostic and predictive factors of cabozantinib vs placebo in previously treated liver cancer, and outcomes based on clinical characteristics and...
Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma
Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, discusses findings from a study that showed new staging criteria should be considered for patients diagnosed with liver metastases in the absence of other extrahepatic tumor spread (Abstract 731P).
Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil
Angela Lamarca, MD, PhD, of The Christie NHS Foundation Trust and the University of Manchester, discusses phase III findings from a multicenter study of active symptom control alone or active symptom control with oxaliplatin and fluorouracil for patients with locally advanced or metastatic biliary...
Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib
Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses an analysis of survival and objective response in patients with hepatocellular carcinoma who took part in a phase III study of lenvatinib (Abstract 186).
Heinz-Josef Lenz, MD, on BRAF V600E–Mutated Biliary Tract Cancer: Results From the ROAR Basket Trial
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E–mutated biliary tract cancer (Abstract 187).
Ahmed Omar Kaseb, MD, on Liver Cancer: Results From an Immunotherapy Trial
Ahmed Omar Kaseb, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on nivolumab alone vs nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (Abstract 185).
Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as targeted therapy for biliary cancer.
Anne M. Covey, MD, on HCC: Screening and Diagnosis Updates
Anne M. Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest recommendations for screening and diagnosing hepatocellular carcinoma, an aggressive tumor marked by increasing incidence in the United States and a poor 5-year survival rate.
Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).
Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).
Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) for biliary tract cancer (LBA29).
John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial
John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing findings on adjuvant capecitabine for biliary tract cancer. (Abstract 4006)
Ann-Lii Cheng, MD, PhD, on Hepatocellular Carcinoma: Trial Results on Lenvatinib vs Sorafenib
Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)
Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial (Spanish Language Version) 
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial (French Language Version) 
Julien Edeline, MD, of the Centre Eugène Marquis, discusses in French study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.
Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial
Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (Abstract 4003).
Anne Covey, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.
Daniel T. Chang, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment
Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.
Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline...
Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
